SCHEMBL208544

SCHEMBL208544

CC(C)(C)OC(=O)NCc1ccc(C=O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.57
NR1H4 Q96RI1 1/20 0.57
L3MBTL1 Q9Y468 2/20 0.52
NAMPT P43490 2/20 0.50
GAA P10253 1/20 0.50
CA1 P00915 2/20 0.47
CA2 P00918 1/20 0.47
HDAC1 Q13547 2/20 0.46
MAPT P10636 3/20 0.44
TDP1 Q9NUW8 1/20 0.44
RECQL P46063 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
KDM4A O75164 1/20 0.44
CA12 O43570 1/20 0.43
CA7 P43166 1/20 0.43
CA14 Q9ULX7 1/20 0.43
SDCBP O00560 1/20 0.43
SDC2 P34741 1/20 0.43
ATM Q13315 1/20 0.43
KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3180689 0.88 L3MBTL1 (0.61) L3MBTL1NAMPTGAACA1CA2
SCHEMBL31318871 0.87 EPHX2 (0.46) EPHX2NR1H4L3MBTL1NAMPTGAA
SCHEMBL24892213 0.87 NAMPT (0.62) EPHX2NR1H4L3MBTL1NAMPTHDAC1
SCHEMBL19853209 0.86 L3MBTL1 (0.51) EPHX2NR1H4L3MBTL1NAMPTGAA
SCHEMBL694492 0.86 L3MBTL1 (0.53) L3MBTL1NAMPTGAACA1CA2
SCHEMBL693427 0.85 CA2 (0.53) EPHX2NR1H4NAMPTCA1CA2
SCHEMBL3307112 0.84 L3MBTL1 (0.52) L3MBTL1NAMPTGAACA1CA2
SCHEMBL3243222 0.84 NAMPT (0.49) L3MBTL1NAMPTGAACA1CA2
SCHEMBL3243218 0.84 NAMPT (0.49) L3MBTL1NAMPTGAACA1CA2
SCHEMBL17104385 0.83 NR1H4 (0.47) EPHX2NR1H4L3MBTL1NAMPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118221551-A Preparation method of tert-butyl 4-formylbenzyl carbamate 南京艾康生物科技有限公司 2024-06-21 CN claimed
US-20030092634-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. 2003-05-15 US claimed
US-6506733-B1 Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. AXYS PHARMACEUTICALS, INC. 2003-01-14 US claimed
EP-1159260-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2001-12-05 EP claimed
WO-2000055124-A2 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2000-09-21 WO claimed
EP-4034094-B1 PHOSPHODIESTERASE INHIBITORS AND USE ZENSHINE PHARMACEUTICALS NANJING GROUP CO LTD (CN) 2026-04-15 EP disclosed
EP-4720044-A1 AROMATIC AMIDES AND CONJUGATES THEREOF AS BINDERS TO TEAD Beactica Therapeutics AB (SE) 2026-04-08 EP disclosed
US-12570610-B2 Macromolecule-supported aminobenzazepine compounds BOLT BIOTHERAPEUTICS, INC. (US) 2026-03-10 US disclosed
EP-4635969-A1 NOVEL GLUCOCORTICOID, METHOD FOR PREPARING SAME, AND USE THEREOF Tianjin Pharmaceutical Biotechnology Co., Ltd. (CN) 2025-10-22 EP disclosed
EP-4618974-A1 OREXIN RECEPTOR AGONISTS Merck Sharp & Dohme LLC (US) 2025-09-24 EP disclosed
US-20250263392-A1 AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF BOLT BIOTHERAPEUTICS, INC. (US) 2025-08-21 US disclosed
EP-4419525-B1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LTD (GB) 2025-07-23 EP disclosed
WO-2002022599-A2 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2002-03-21 WO disclosed
EP-1159260-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2001-12-05 EP disclosed
WO-2000055124-A2 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2000-09-21 WO disclosed
CN-1215054-A Bychclic fibrinogen antagonists SMITHKLINE BEECHAM CORP (US) 1999-04-28 CN disclosed
CN-1041921-C Bicyclic fibrinogen antagonists SMITHKLINE BEECHAM CORP (US) 1999-02-03 CN disclosed
EP-0674623-A1 BICYCLIC FIBRINOGEN ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1995-10-04 EP disclosed
CN-1094718-A Bicyclic fibrinogen antagonists SMITHKLINE BEECHAM CORP (US) 1994-11-09 CN disclosed
WO-1994014776-A2 BICYCLIC FIBRINOGEN ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1994-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250263392-A1 AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF IDO2, IDO1, BCR EPHX2 465/4885NR1H4 229/4885L3MBTL1 4075/4885
US-20030092634-A1 Novel compounds and compositions as protease inhibitors SERPINB1, HPN, CTRL EPHX2 800/4885NR1H4 2694/4885L3MBTL1 3703/4885
US-12570610-B2 Macromolecule-supported aminobenzazepine compounds BCL6, CLTB, MET EPHX2 3769/4885NR1H4 610/4885L3MBTL1 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.